Amplia Therapeutics (ATX) TRADING HALT SUSPENDED

20mins delayed

Movement

1 Year Return


Amplia Therapeutics Chart

Share price
Last
Change
Volume
Turnover
Market Cap $5.98 million
Today's Movement
Prev. Close
Open
Day Range -
VWAP
Historical Stats
52w Range -
4w Avg Volume
4w Avg Turnover
(delayed)
Free until 29 Feb

The BIGGEST ASX
Spreadsheet yet!

Download in Excel or PDF for printing

Data on 1,800+ ASX Companies

  • 12-month Price Targets

  • EPS & Dividends

  • 52w Highs & Lows

It's FREE until 29 February

The BIGGEST ASX Spreadsheet yet! Current Price vs 1 Yr Target Current Price from 52w High Broker Consensus Share Price Data Fundamentals Broker Consensus

ATX Statistics

21 February

1,927 / 2,267

ASX Size Rank

1yr Return

vs Sector (1yr)

-86.09%

vs ASX 200 (1yr)

-38.03%

$5.98 million

Market Cap

Share Issue

66.46 million

All Ords (%)

N/A

Short Sold

0%

Current Fundamentals

21 February

N/A

PE Ratio

EPS ($)

-0.047

Earnings Yield

-52.22%

NTA ($)

0.02

N/A

Dividend Yield

DPS ($)

-

Gross Div. Yield

-

Gross DPS ($)

-

Company Overview

Amplia Therapeutics Limited (ATX, formerly Innate Immunotherapeutics Limited) is an Australian pharmaceutical company that is advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus in pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF).

Former Names
Innate Immunotherapeutics Limited (IIL), 07/09/2018

Amplia Therapeutics Logo

Corporate Details

Head Office: Melbourne
Managing Director: John Lambert
GICS Sub-Industry: Biotechnology
Date Listed: 23 Dec 2013
Registry: Computershare
Similar Companies: CSL / AVH / MSB / CUV / OPT

Upcoming Calendar

27 May 2020 Report (Prelim)
23 Jul 2020 Report (Annual)
27 Nov 2020 Report (Interim)

Dividend History

Ex-Date Amount Franking Type Payable
No dividends paid in the last 5 years

See Upcoming Dividends for all ASX companies.

Announcements

Date Heading Pages File Size Time

Broker Consensus

The buy, hold and sell recommendations from Australian stockbroking firms are combined to form a "broker consensus". See the Consensus Data posts for more information.

ATX is not covered by a major broker,
or data from most recent compilation was omitted due
to not meeting QA guidelines.

Directors & Management

About the Data


Name Title Since Bio
Mr Andrew John Cooke Company Secretary Oct 2013
Dr John Lambert Chief Executive Officer, Managing Director Jun 2019
Dr Robert Peach Non-Executive Director Sep 2015
Dr Warwick Bonner Tong Non-Executive Director, Non-Executive Chairman May 2018
Dr Christopher John Burns Non-Executive Director May 2018

Director Transactions

About the Data

ATX directors must report any change in shareholding to the ASX within 5 business days.

See Director Transactions for all ASX companies.

Date Director Type Amount Price Value Notes
17/09/19 Robert Peach Transfer 56,000 $0.080 $4,480 Off-market transfer.
17/09/19 Robert Peach Issued 500,000 $0.080 $40,000 Placement.
17/09/19 Robert Peach Issued 1,000,000 $0.100 $100,000 Placement.
17/09/19 Christian Behrenbruch Issued 250,000 $0.100 $25,000 Placement.
17/09/19 Christian Behrenbruch Issued 125,000 $0.080 $10,000 Placement.
17/09/19 Warwick Tong Issued 250,000 $0.100 $25,000 Placement.
17/09/19 Warwick Tong Issued 125,000 $0.080 $10,000 Placement.
20/08/19 Simon Wilkinson Expiry 175,000 $0.077 $13,475 Options expired.
02/08/19 Andrew Cooke Issued 125 $10.000 $1,250 Rights issue.
02/08/19 Andrew Cooke Issued 63 $0.095 $6 Rights issue.
02/08/19 Warwick Tong Issued 40,000 $0.098 $3,920 Rights issue.
02/08/19 Warwick Tong Issued 80,000 $0.100 $8,000 Rights issue.
02/08/19 Christopher Burns Issued 60,000 $0.100 $6,000 Rights issue.
02/08/19 Christopher Burns Issued 30,000 $0.098 $2,940 Rights issue.
06/11/18 Andrew Cooke Buy +120 $0.308 $37 Off-market trade.
05/11/18 Simon Wilkinson Expiry 100,000 $0.270 $27,000 Options expired.
31/08/18 Andrew Cooke Issued 480,000 $0.370 $177,600 Issue of options.
31/08/18 Simon Wilkinson Issued 1,370,000 $0.370 $506,900 Issue of securities.
31/08/18 Simon Wilkinson Expiry 175,000 $0.370 $64,750 Options expired.
31/08/18 Robert Peach Expiry 100,000 $0.370 $37,000 Options expired.
31/08/18 Robert Peach Issued 480,000 $0.370 $177,600 Issue of options.

Shareholder Distribution

About the Data

Holding Size 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over Total Shareholders
No. of Shareholders 1,767 656 192 225 44 2,884

Top 20 Shareholders

About the Data

Name Shares Capital
Citicorp Nominees Pty Limited 6,357,072 14.25%
CTXT Pty Ltd 4,514,468 10.12%
Elk River Holdings Pty Ltd 2,492,142 5.58%
34th Avenue Pty Ltd 2,215,237 4.96%
Christopher John Burns 2,215,237 4.96%
Warwick Tong 1,661,428 3.72%
Mark Sullivan 1,661,428 3.72%
Cancer Research Technology Limited 1,360,524 3.05%
Merrill Lynch (Australia) Nominees Pty Limited 1,160,610 2.60%
Margaret Frame 923,016 2.07%
Neil Oliver Carragher 553,809 1.24%
Mr Ian Heraud + Mrs Fiona Heraud 500,000 1.12%
Ms Caitlin Collins 500,000 1.12%
National Nominees Limited 500,000 1.12%
Yelwac Pty Ltd 400,000 0.90%
Symington Pty Ltd 400,000 0.90%
Mrs Patricia Watkins + Mr John Phibbs + Mr Graeme Halse 377,750 0.85%
Probe International Inc 369,269 0.83%
Mr Andrew Podolak 360,000 0.81%
Chep LI LLC 352,532 0.79%
All other shareholders 35.29 %


The Top 20 Shareholders of ATX hold 64.71% of shares on issue.

ATX Share Price History

Date Close Change % Change Open High Low Volume Turnover

ATX Historical Data

Download up to 20 years of share price history.


Year Closing Price (30 June) Last Trade

Offical data as published by ASX. See more Data Downloads.

Company Details

Principal Activity: Development of these drug candidates for potential use in multiple indications including immuno-oncology and chronic fibrosis.

Incorporated: --

Level 29, 55 Collins St
Melbourne VIC 3000


All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.